Matches in SemOpenAlex for { <https://semopenalex.org/work/W1988401045> ?p ?o ?g. }
- W1988401045 endingPage "S10" @default.
- W1988401045 startingPage "S1" @default.
- W1988401045 abstract "Despite the introduction of newer chemotherapeutic agents such as irinotecan, capecitabine and oxaliplatin, patients with metastatic colorectal cancer (mCRC) still have a poor prognosis. More effective and better-tolerated treatment strategies are needed to improve patient outcomes, particularly in subsequent lines of treatment following chemotherapy failure. The favourable efficacy and acceptable safety profiles of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) have led to the approval of panitumumab and cetuximab monotherapy for the treatment of patients with EGFR-expressing mCRC whose tumours express non-mutated (wildtype) KRAS, after failure of standard chemotherapy. Cetuximab is also approved in combination with chemotherapy for the treatment of mCRC in this patient population. In phase III monotherapy studies, panitumumab and cetuximab demonstrated significant improvements in progression-free survival when administered with best supportive care (BSC) vs. BSC alone in chemotherapy-refractory mCRC patients. A planned retrospective analysis of the panitumumab monotherapy trial was the first large-scale clinical demonstration that efficacy was confined to patients with tumours expressing wild-type KRAS. It is now recognised that anti-EGFR mAb therapy should only be used in patients whose tumours express wild-type KRAS. While generally well tolerated, anti-EGFR mAb monotherapy is associated with skin toxicity, and severity of the skin rash has been proposed as an early marker of response to treatment. BRAF, PTEN, and PI3K are also emerging as future potential predictive markers of response; however, further clinical studies are warranted to define the role of these biomarkers." @default.
- W1988401045 created "2016-06-24" @default.
- W1988401045 creator A5051648139 @default.
- W1988401045 creator A5064981456 @default.
- W1988401045 creator A5067038598 @default.
- W1988401045 creator A5077000250 @default.
- W1988401045 date "2010-02-01" @default.
- W1988401045 modified "2023-09-27" @default.
- W1988401045 title "The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer" @default.
- W1988401045 cites W153228381 @default.
- W1988401045 cites W1965996783 @default.
- W1988401045 cites W1967054917 @default.
- W1988401045 cites W1968151389 @default.
- W1988401045 cites W1968282664 @default.
- W1988401045 cites W1971409545 @default.
- W1988401045 cites W1978348877 @default.
- W1988401045 cites W1991679954 @default.
- W1988401045 cites W1993397416 @default.
- W1988401045 cites W2000194757 @default.
- W1988401045 cites W2002472253 @default.
- W1988401045 cites W2010928484 @default.
- W1988401045 cites W2016206649 @default.
- W1988401045 cites W2017005150 @default.
- W1988401045 cites W2020830322 @default.
- W1988401045 cites W2028035144 @default.
- W1988401045 cites W2028083041 @default.
- W1988401045 cites W2035454562 @default.
- W1988401045 cites W2036645516 @default.
- W1988401045 cites W2038386885 @default.
- W1988401045 cites W2038828905 @default.
- W1988401045 cites W2039633811 @default.
- W1988401045 cites W2040640655 @default.
- W1988401045 cites W2042450112 @default.
- W1988401045 cites W2048964513 @default.
- W1988401045 cites W2048996882 @default.
- W1988401045 cites W2049159592 @default.
- W1988401045 cites W2051311685 @default.
- W1988401045 cites W2057763602 @default.
- W1988401045 cites W2058934913 @default.
- W1988401045 cites W2064035676 @default.
- W1988401045 cites W2072617189 @default.
- W1988401045 cites W2073699264 @default.
- W1988401045 cites W2083102922 @default.
- W1988401045 cites W2084653234 @default.
- W1988401045 cites W2085743219 @default.
- W1988401045 cites W2086610669 @default.
- W1988401045 cites W2087579890 @default.
- W1988401045 cites W2093773160 @default.
- W1988401045 cites W2094410967 @default.
- W1988401045 cites W2095201384 @default.
- W1988401045 cites W2097121246 @default.
- W1988401045 cites W2100471896 @default.
- W1988401045 cites W2100490225 @default.
- W1988401045 cites W2100589633 @default.
- W1988401045 cites W2100751422 @default.
- W1988401045 cites W2101472517 @default.
- W1988401045 cites W2101995865 @default.
- W1988401045 cites W2102601598 @default.
- W1988401045 cites W2106475544 @default.
- W1988401045 cites W2106555579 @default.
- W1988401045 cites W2106789440 @default.
- W1988401045 cites W2108362303 @default.
- W1988401045 cites W2108468456 @default.
- W1988401045 cites W2110108978 @default.
- W1988401045 cites W2110803737 @default.
- W1988401045 cites W2114048774 @default.
- W1988401045 cites W2118971132 @default.
- W1988401045 cites W2120490763 @default.
- W1988401045 cites W2121785313 @default.
- W1988401045 cites W2122618533 @default.
- W1988401045 cites W2125229905 @default.
- W1988401045 cites W2125447919 @default.
- W1988401045 cites W2125903425 @default.
- W1988401045 cites W2127671551 @default.
- W1988401045 cites W2131413118 @default.
- W1988401045 cites W2133399075 @default.
- W1988401045 cites W2135973021 @default.
- W1988401045 cites W2140510616 @default.
- W1988401045 cites W2142564546 @default.
- W1988401045 cites W2143743735 @default.
- W1988401045 cites W2144425748 @default.
- W1988401045 cites W2144648936 @default.
- W1988401045 cites W2147718573 @default.
- W1988401045 cites W2148156299 @default.
- W1988401045 cites W2150286564 @default.
- W1988401045 cites W2155311724 @default.
- W1988401045 cites W2156700619 @default.
- W1988401045 cites W2157769714 @default.
- W1988401045 cites W2158863975 @default.
- W1988401045 cites W2158997283 @default.
- W1988401045 cites W2162315065 @default.
- W1988401045 cites W2164194457 @default.
- W1988401045 cites W2164837623 @default.
- W1988401045 cites W2165741055 @default.
- W1988401045 cites W2167539263 @default.
- W1988401045 cites W2168213749 @default.
- W1988401045 cites W2171111432 @default.
- W1988401045 cites W2409420104 @default.